Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases
Stopped early · Phase 1
Conditions studied: Liver Cancer
In brief
Up to twenty-two patients will be enrolled in this study to receive autologous dendritic cells (DCs) administered intratumorally into liver metastases following radiofrequency thermal ablation of those lesions. Patients will receive two vaccinations of DCs at monthly intervals. A dose escalation study of DCs will be included in this study in an attempt to define the maximum tolerated dose of administered DCs.
Key facts
- Study ID
- NCT00185874
- Run by
- Stanford University
- People needed
- 22
- Starts
- 2004-01-01
- Expected to finish
- 2007-10-01
- Last updated by the study team
- 2010-01-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.